A Phase I, Open-Label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of a Single Oral Dose of RVX000222 in Subjects with Severe Renal Impairment.
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Apabetalone (Primary)
- Indications Renal impairment
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Resverlogix Corporation
- 29 Mar 2018 Results published in a Kidney International Reports.
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 29 Aug 2017 Data from this trial presented at the European Society of Cardioligists (ESC) Congress 2017, according to a Resverlogix Corporation media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History